Klaria Pharma Holding AB and its subsidiary company Cannabis Delivery Sciences (CDS) today announced that Chilam Enterprise Ltd has entered into a non-exclusive license agreement with CDS for the right to sell CDS’ Cannabis Alginate Films in Europe.
Chilam will supply the European medical sector with medicinal cannabis both as a white label manufacturer to third parties and as directly under its own brands. Chilam specializes in cannabis research, cultivation, production and distribution. Focused on developing science-backed medical and derivative cannabis products, Chilam is using Genofarm’s expertise in seeds genetics to commit to produce GMP-compliant medical cannabis – both dried flower and oil in accordance with European Union standards, in its manufacturing facility in North Macedonia.
Enterprising visionaries with deep industry knowledge, scientific and technical expertise, Chilam were founded in 2019 with the vision to bring premium and effective cannabis products to the medical-use market. Our team of experts and international business leaders formed a solid business model leveraging the emerging European market to become the leading medical cannabis producer and distributor in Europe.
This partnership will enable Chilam to export a greater range of medical cannabis products that includes the Alginate Film to international patients and markets with legal medical cannabis regulations. By combining the next-generation CDS delivery technology with Chilam’s highly standardized quality cannabis strains, Chilam aims to acquire significant market-share in the European medical cannabis sector.
It is an exciting time for us as we have an optimal delivery technology which is patented and brings pharma-grade delivery precision to the sector. It is our goal to become the de-facto delivery technology in the Medicinal Cannabis industry. This is an important milestone for our strategic growth in the international medical cannabis market. We look forward to supplying pharmaceutical-grade cannabis products, proudly produced in North-Macedonia. The Cannabis Alginate Film will be an important part in our product portfolio”, says George Meek, CEO & co-founder at Chilam Enterprise Ltd.
Cannabis Delivery Sciences is a subsidiary of Klaria Pharma Holding AB (publ), and has secured an exclusive and perpetual world-wide license to Klaria’s Alginate Film Technology for both medicinal and recreational use of all cannabinoids, including CBD and THC. The company is led by an international management team with experience from the United States, Canada, Jamaica, and the UK in entrepreneurial companies focused on the marketing of luxury goods and high-end spirits as well as on pharmaceutical development
